Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 583

1.

Asymptomatic Deep Vein Thrombosis is Associated with an Increased Risk of Death: Insights from the APEX Trial.

Kalayci A, Gibson CM, Chi G, Yee MK, Korjian S, Datta S, Nafee T, Gurin M, Haroian N, Qamar I, Hull RD, Hernandez AF, Cohen AT, Harrington RA, Goldhaber SZ.

Thromb Haemost. 2018 Nov 12. doi: 10.1055/s-0038-1675606. [Epub ahead of print]

PMID:
30419597
2.

CSL112, a reconstituted, infusible, plasma-derived apolipoprotein A-I: safety and tolerability profiles and implications for management in patients with myocardial infarction.

Capodanno D, Mehran R, Gibson CM, Angiolillo DJ.

Expert Opin Investig Drugs. 2018 Nov 3:1-9. doi: 10.1080/13543784.2018.1543399. [Epub ahead of print]

PMID:
30376729
3.

Usefulness of Rivaroxaban for Secondary Prevention of Acute Coronary Syndrome in Patients With History of Congestive Heart Failure (from the ATLAS-ACS-2 TIMI-51 Trial).

Korjian S, Braunwald E, Daaboul Y, Mi M, Bhatt DL, Verheugt FWA, Cohen M, Bode C, Burton P, Plotnikov AN, Gibson CM.

Am J Cardiol. 2018 Sep 7. pii: S0002-9149(18)31733-8. doi: 10.1016/j.amjcard.2018.08.034. [Epub ahead of print]

4.

Betrixaban for first-line venous thromboembolism prevention in acute medically ill patients with risk factors for venous thromboembolism.

Nafee T, Gibson CM, Yee MK, Alkhalfan F, Chi G, Travis R, Mir M, Kalayci A, Jafarizade M, Ganti A, Kazmi SH, Ghaffarpasand E, Pitliya A, Datta S, Sharfaei S, Alihashemi M, Elsaiey A, Qamar I, Jahansouz M, Talib U, Kahe F, Habibi S, Abdelwahed M, Tariq F, Kaur M, Younes A, Walia SS, Singh A, Dildar SM, Afzal MK, Kerneis M.

Expert Rev Cardiovasc Ther. 2018 Nov;16(11):845-855. doi: 10.1080/14779072.2018.1534068. Epub 2018 Oct 15.

PMID:
30296387
5.

Conundrum of Using Real-World Observational Data to Inform Real-World Conclusions About Safety and Efficacy.

Gibson CM, Nafee T, Kerneis M.

J Am Coll Cardiol. 2018 Oct 9;72(15):1801-1803. doi: 10.1016/j.jacc.2018.07.053. No abstract available.

PMID:
30286923
6.

Inverse relationship of serum albumin to the risk of venous thromboembolism among acutely ill hospitalized patients: Analysis from the APEX trial.

Chi G, Gibson CM, Liu Y, Hernandez AF, Hull RD, Cohen AT, Harrington RA, Goldhaber SZ.

Am J Hematol. 2018 Sep 25. doi: 10.1002/ajh.25296. [Epub ahead of print]

PMID:
30252149
7.

Modes and timing of death in 66 252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials.

Berg DD, Wiviott SD, Braunwald E, Guo J, Im K, Kashani A, Gibson CM, Cannon CP, Morrow DA, Bhatt DL, Mega JL, O'Donoghue ML, Antman EM, Newby LK, Sabatine MS, Giugliano RP.

Eur Heart J. 2018 Nov 7;39(42):3810-3820. doi: 10.1093/eurheartj/ehy556.

PMID:
30239711
8.

D-Dimer Levels and Effect of Rivaroxaban on Those Levels and Outcomes in Patients With Acute Coronary Syndrome (An ATLAS ACS-TIMI 46 Trial Substudy).

AlKhalfan F, Kerneis M, Nafee T, Yee MK, Chi G, Plotnikov A, Braunwald E, Gibson CM.

Am J Cardiol. 2018 Nov 1;122(9):1459-1464. doi: 10.1016/j.amjcard.2018.07.032. Epub 2018 Aug 4.

PMID:
30217378
9.

Maximizing Benefits With the Medication Use Evaluation Process.

Davis S, Rungruangphol PD, Gibson CM.

Hosp Pharm. 2018 Oct;53(5):284-285. doi: 10.1177/0018578718775330. Epub 2018 May 8. No abstract available.

PMID:
30210143
10.

Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial.

Stone GW, Généreux P, Harrington RA, White HD, Gibson CM, Steg PG, Hamm CW, Mahaffey KW, Price MJ, Prats J, Deliargyris EN, Bhatt DL.

Eur Heart J. 2018 Sep 9. doi: 10.1093/eurheartj/ehy562. [Epub ahead of print]

PMID:
30203006
11.

Reply: In Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention, One Size Cannot Fit All.

Kerneis M, Gibson CM, Cohen M.

JACC Cardiovasc Interv. 2018 Aug 13;11(15):1539-1540. doi: 10.1016/j.jcin.2018.04.028. No abstract available.

PMID:
30093062
12.

Wildfire as a major driver of recent permafrost thaw in boreal peatlands.

Gibson CM, Chasmer LE, Thompson DK, Quinton WL, Flannigan MD, Olefeldt D.

Nat Commun. 2018 Aug 2;9(1):3041. doi: 10.1038/s41467-018-05457-1.

13.

SECURE PCI: how important can a subgroup analysis be?

Kerneis M, Yee MK, Gibson CM.

J Thorac Dis. 2018 Jun;10(Suppl 17):S2032-S2034. doi: 10.21037/jtd.2018.05.155. No abstract available.

14.

Safety and efficacy of non-vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: A bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trial.

Chi G, Kerneis M, Kalayci A, Liu Y, Mehran R, Bode C, Halperin JL, Verheugt FWA, Wildgoose P, van Eickels M, Lip GYH, Cohen M, Peterson ED, Fox KAA, Gibson CM.

Am Heart J. 2018 Sep;203:17-24. doi: 10.1016/j.ahj.2018.06.003. Epub 2018 Jun 13.

PMID:
30015064
15.

Fatal or Irreversible Bleeding and Ischemic Events With Rivaroxaban in Acute Coronary Syndrome.

Gibson CM, Levitan B, Gibson WJ, Yee MK, Murphy SA, Yuan Z, Chakrabarti AK, Lee M, Braunwald E.

J Am Coll Cardiol. 2018 Jul 10;72(2):129-136. doi: 10.1016/j.jacc.2018.04.055.

PMID:
29976285
16.

Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention.

Capodanno D, Mehran R, Valgimigli M, Baber U, Windecker S, Vranckx P, Dangas G, Rollini F, Kimura T, Collet JP, Gibson CM, Steg PG, Lopes RD, Gwon HC, Storey RF, Franchi F, Bhatt DL, Serruys PW, Angiolillo DJ.

Nat Rev Cardiol. 2018 Aug;15(8):480-496. doi: 10.1038/s41569-018-0049-1. Review.

PMID:
29973709
17.

Moving From Hope to Hard Work in Data Sharing.

Gibson CM.

JAMA Cardiol. 2018 Sep 1;3(9):795-796. doi: 10.1001/jamacardio.2018.0130. No abstract available.

PMID:
29971341
18.

Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary intervention.

Chi G, Yee MK, Kalayci A, Kerneis M, AlKhalfan F, Mehran R, Bode C, Halperin JL, Verheugt FWA, Wildgoose P, van Eickels M, Lip GYH, Cohen M, Peterson ED, Fox KAA, Gibson CM.

J Thromb Thrombolysis. 2018 Oct;46(3):346-350. doi: 10.1007/s11239-018-1703-5.

PMID:
29943350
19.

Definitions of peri-procedural myocardial infarction and the association with one-year mortality: Insights from CHAMPION trials.

Olivier CB, Sundaram V, Bhatt DL, Leonardi S, Lopes RD, Ding VY, Yang L, Stone GW, Steg PG, Gibson CM, Hamm CW, Price MJ, White HD, Desai M, Lynch DR Jr, Harrington RA, Mahaffey KW; CHAMPION PLATFORM and CHAMPION PCI Investigators.

Int J Cardiol. 2018 Nov 1;270:96-101. doi: 10.1016/j.ijcard.2018.06.034. Epub 2018 Jun 8.

PMID:
29937301
20.

Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention: Results From the PARIS Registry (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients).

Baber U, Li SX, Pinnelas R, Pocock SJ, Krucoff MW, Ariti C, Gibson CM, Steg PG, Weisz G, Witzenbichler B, Henry TD, Kini AS, Stuckey T, Cohen DJ, Iakovou I, Dangas G, Aquino MB, Sartori S, Chieffo A, Moliterno DJ, Colombo A, Mehran R.

Circ Cardiovasc Interv. 2018 Mar;11(3):e006144. doi: 10.1161/CIRCINTERVENTIONS.117.006144.

PMID:
29870385

Supplemental Content

Loading ...
Support Center